Full text is available at the source.
Abstract
The safety and tolerability of a novel oral modified-release psilocybin formulation (REL-P11) were evaluated in healthy adults.
- The study included both normal-weight and overweight/obese participants.
- Pharmacokinetics were assessed to understand how the body processes the new formulation.
- The formulation aims for controlled, subperceptual exposure to psilocybin.
- Emerging evidence suggests that serotonergic modulation could play a role in metabolic disorders.
Simplified
Psychedelic Science